AU2009205477A1 - Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss - Google Patents

Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss Download PDF

Info

Publication number
AU2009205477A1
AU2009205477A1 AU2009205477A AU2009205477A AU2009205477A1 AU 2009205477 A1 AU2009205477 A1 AU 2009205477A1 AU 2009205477 A AU2009205477 A AU 2009205477A AU 2009205477 A AU2009205477 A AU 2009205477A AU 2009205477 A1 AU2009205477 A1 AU 2009205477A1
Authority
AU
Australia
Prior art keywords
compound
prodrug
pharmaceutically acceptable
acceptable salt
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009205477A
Other languages
English (en)
Inventor
Robert M. Burk
Danny T. Dinh
David W. Old
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AU2009205477A1 publication Critical patent/AU2009205477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2009205477A 2008-01-18 2009-01-14 Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss Abandoned AU2009205477A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2217208P 2008-01-18 2008-01-18
US61/022,172 2008-01-18
US12/352,903 US8063033B2 (en) 2008-01-18 2009-01-13 Therapeutic beta-lactams
US12/352,903 2009-01-13
PCT/US2009/030894 WO2009091764A2 (en) 2008-01-18 2009-01-14 Therapeutic beta-lactams

Publications (1)

Publication Number Publication Date
AU2009205477A1 true AU2009205477A1 (en) 2009-07-23

Family

ID=40876971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009205477A Abandoned AU2009205477A1 (en) 2008-01-18 2009-01-14 Beta-lactams for the treatment of glaucoma, ocular hypertension, baldness and hair loss

Country Status (7)

Country Link
US (1) US8063033B2 (enExample)
EP (1) EP2321304A2 (enExample)
JP (1) JP2011510009A (enExample)
AU (1) AU2009205477A1 (enExample)
BR (1) BRPI0906846A2 (enExample)
CA (1) CA2712264A1 (enExample)
WO (1) WO2009091764A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
PL2155733T3 (pl) * 2007-05-23 2013-02-28 Allergan Inc Cykliczne laktamy do leczenia jaskry lub podwyższonego ciśnienia śródgałkowego
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) * 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
JPH08504765A (ja) 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換５−チアピリミジノンおよび５−セレノピリミジノン化合物
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) * 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EA200300379A1 (ru) * 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
JP2004521954A (ja) * 2001-07-16 2004-07-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｅｐ４受容体作用薬としてのプロスタグランジン類似体
ES2246419T3 (es) * 2001-11-05 2006-02-16 Allergan, Inc. Analogos de omega-cicloalquil-17-heteroaril-prostaglandina e2 como agonistas del receptor ep-2.
ATE336247T1 (de) * 2002-03-18 2006-09-15 Pfizer Prod Inc Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US7091231B2 (en) * 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
CA2602535A1 (en) * 2005-05-06 2006-11-16 Allergan, Inc. Substituted beta-lactams and their use in medicine
WO2006121822A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Also Published As

Publication number Publication date
BRPI0906846A2 (pt) 2015-07-07
JP2011510009A (ja) 2011-03-31
US20090186866A1 (en) 2009-07-23
US8063033B2 (en) 2011-11-22
EP2321304A2 (en) 2011-05-18
WO2009091764A3 (en) 2010-01-21
WO2009091764A2 (en) 2009-07-23
CA2712264A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
US7820661B2 (en) Substituted gamma lactams as therapeutics agents
AU2009225706B2 (en) Therapeutic substituted cyclopentanes
US7737140B2 (en) Therapeutic compounds
US8063033B2 (en) Therapeutic beta-lactams
AU2009225693B2 (en) Therapeutic compounds
EP2285775B1 (en) Lactams and their use in the treatment of inter alia ocular hypertension or baldness
US7879854B2 (en) Substituted gamma lactams as therapeutic agents
AU2009244541B2 (en) Therapeutic compounds
US8202855B2 (en) Substituted beta-lactams
US8541603B2 (en) Substituted cyclopentanes or cyclopentanones as therapeutic agents
US7981887B2 (en) Therapeutic compounds
WO2006121822A1 (en) USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US7956055B2 (en) Substituted gamma lactams as therapeutic agents
US7964596B2 (en) Therapeutic compounds
CA2728227A1 (en) Therapeutic cyclopentane derivatives

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application